2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2609

A Systematic Literature Mining and Gene Expression Analysis Identifies Possible Drug Candidates for Repositioning in Lupus
Abstract Number: 2610

Quantiferon Testing in a Clinical Trial of Systemic Lupus Erythematosus
Abstract Number: 2611

Walk SLE – a Pilot Study Exploring Walk with Ease (WWE), a Self-Directed Walking Program, in Lupus Patients
Abstract Number: 2612

Disparities in Antimalarial Prescribing for Systemic Lupus Erythematosus Using a Real-World, Electronic Health Record
Abstract Number: 2613

Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients
Abstract Number: 2614

Hydroxychloroquine Initiation Dosing Trends and Predictors in Systemic Lupus Erythematosus
Abstract Number: 2615

Non-Pharmacological Treatment on Fatigue, Depression, Disease Activity, and Quality of Life of Systemic Lupus Erythematosus: A Systematic Review
Abstract Number: 2616

Mesenchymal Stem Cells Induce CD1c+ Tolerogenic Dendritic Cells Via up-Regulating FLT3L in Systemic Lupus Erythematosus
Abstract Number: 2617

Electrocardiogram Abnormalities Related to Antimalarials in Systemic Lupus Erythematosus
Abstract Number: 2618

Why Aren’t All Patients with SLE Taking Hydroxychloroquine? A Retrospective Chart Review
Abstract Number: 2619

Hemophagocytic Syndrome in Patients from SLE Registry from the Spanish Society of Rheumatology (RELESSER)
Abstract Number: 2620

The Value of Repeat Biopsy in the Management of Lupus Nephritis Flares
Abstract Number: 2621

Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution
Abstract Number: 2622

The Benefit of Vitamin D on SLE Disease Activity Is Largely Explained By Renal Activity
Abstract Number: 2623

Association between Smoking Status and the Clinical and Serological Characteristics at the Onset of Systemic Lupus Erythematosus. an Inception Cohort Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].